Impactos do tratamento com liraglutida na progressão da doença renal crônica em pacientes com diabetes mellitus tipo 2 / Impacts of treatment with liraglutide on the progression of chronic kidney disease in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.34119/bjhrv3n4-362Keywords:
Liraglutida, Insuficiência Renal Crônica, Diabetes Mellitus, Incretinas, Albuminúria.Abstract
INTRODUÇÃO: A doença renal diabética é uma importante complicação decorrente da diabetes mellitus tipo 2. O estudo visa analisar o impacto da utilização da liraglutida, um fármaco agonista de GLP-1, no controle desse agravo. METODOLOGIA: Foi realizada uma revisão narrativa baseada em artigos encontrados entre os anos 2016 e 2020, nas bases de dados LILACS e PubMed, por meio de consulta ao DeCs, através dos descritores: GLP-1, liraglutide, diabetes mellitus e kidney chronic disease. RESULTADOS: Foram selecionadas 9 publicações para serem utilizadas como referencial para este artigo. DISCUSSÃO: Estudos estão sendo realizados a fim de identificar medicamentos que controlam a glicemia e sejam eficazes na preservação da função renal, assim evidenciou-se a Liraglutida. O fármaco apresentou bons resultados sobre o controle glicêmico, mostrando-se mais eficaz em relação a outros medicamentos. Além disso, foram evidenciados resultados positivos sobre o controle da obesidade e da pressão arterial, sendo esses fatores contribuintes para diminuir a progressão da doença renal diabética. Importante ressaltar também a atuação da liraglutida no sistema renal, reduzindo o declínio da taxa de filtração glomerular e os valores de albuminúria. CONCLUSÃO: A liraglutida se mostrou eficiente na redução da progressão da doença renal crônica em pacientes diabéticos tipo 2.
References
AGUIAR, L. K.; et al. Fatores associados à doença renal crônica: inquérito epidemiológico da Pesquisa Nacional de Saúde. Revista Brasileira de Epidemiologia. Rio de Janeiro, v. 23, 2020.
AMERICAN DIABETES ASSOCIATION. 9. Abordagens farmacológicas do tratamento glicêmico: Standards of Medical Care in Diabetes - 2019. Diabetes Care 2019; 42 (Suppl. 1): S90 – S102. 2019
ANVISA. Victoza (liraglutida): nova indicação. novo nordisk farmacêutico do brasil LTDA, 2019
CARVALHO, D. et al. Agonistas dos Receptores do GLP-1 no Tratamento da Diabetes Tipo 2. Revista Portuguesa de Diabetes, v. 11, n. 4, p. 154-166, 2016.
COHEN, R. V.; et al. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial. JAMA Surgery, p. e01-e11, 2020.
DAVIES, M. J.; et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes care, v. 39, n. 2, p. 222-230, 2016.
DIRETRIZES DA SOCIEDADE BRASILEIRA DE DIABETES,2019-2020. Clanad: editora científica. 2019
DRUCKER, D. J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Biology, Medicine. [S.l], v. 27, n. 4, pp.740-756. 2018.
FERREIRA, A.; et al. Treatment options for type 2 diabetes mellitus in patients with chronic kidney disease-old and new drugs. Portuguese Journal of Nephrology & Hypertension, v. 33, n. 2, p. 98-106, 2019.
GELONEZE, B.; et al. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. Drugs vol. 77,5 : 493-503. 23 fev. 2017.
GÓRRIZ, J. L.; et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, v. 9, n. 4, p. 947, 2020.
HINNEN, D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum, v. 30, n. 3, p. 202-210, 2017.
HTIKE, Z. Z. et al. Efficacy and safety of glucagon?like peptide?1 receptor agonists in type 2 diabetes: a systematic review and mixed?treatment comparison analysis. Diabetes, Obesity and Metabolism, v. 19, n. 4, p. 524-536, 2017.
IOANNIDIS, I. Diabetes treatment in patients with renal disease: Is the landscape clear enough?. World journal of diabetes, v. 5, n. 5, p. 651, 2014.
KAWANAMI, D.; TAKASHI, Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Frontiers in Pharmacology, v. 11, p. 967, 2020.
LUCAS, M. D. G.; et al. Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease. European Journal Of Internal Medicine, [S.L.], v. 44, p. 28-29, out. 2017.
MANN, J. F .E.; et al. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology, v. 15, n. 4, p. 465-473, 2020.
MANN, J. F. E.; et al. Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, v. 377, n. 9, p. 839-848, 2017.
MOLLAOGLU, M. Quality of Life in Patients with Chronic Renal Failure and Some Affecting Factors. Archives Of Renal Diseases And Management, [S.L.], p. 012-019, 29 maio 2017.
NAVARRO-SOLANO, J.; CHEN-KU, C.. Actualización del efecto de los antihiperglicemiantes en la función renal en diabetes mellitus tipo 2. Acta méd. costarric, San José , v. 60, n. 2, p. 6-14, June 2018 .
OSONOI, T.; et al. Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: a 7-year retrospective analysis. Diabetes Technology & Therapeutics, [S.L.], p. 1-4, 12 jun. 2020.
PI-SUNYER, X.; et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, v. 373, n. 1, p. 11-22, 2015.
RONDINELLI, Maurizio; et al. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. Clinical Therapeutics, [S.L.], v. 39, n. 1, p. 159-169, jan. 2017.
SAEEDI, P.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition: Diabetes Research and clinical Practice v 157 , novembro de 2019.
SCHOLTEN, B. J. V.; et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes, Obesity And Metabolism, [S.L.], v. 19, n. 2, p. 239-247, 21 nov. 2016.
SKOV, J. et al. Short?term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, v. 18, n. 6, p. 581-589, 2016.
SLOAN, L. A. Review of glucagon?like peptide?1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of diabetes, v. 11, n. 12, p. 938-948, 2019.
TONNEIJCK, L.; et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care, v. 39, n. 11, p. 2042-2050, 2016.
TOYAMA, T.; et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018;9(9):CD011798. Published 2018 Sep 24.
VILLARINO, A. V.; et al. Mechanisms of Jak/STAT Signaling in Immunity and Disease. The Journal Of Immunology, [S.L.], v. 194, n. 1, p. 21-27, 2015.
ZAVATTARO, M.; et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine, [S.L.], v. 50, n. 3, p. 620-626, 9 jan. 2015.
ZITMAN?GAL, T.; et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db / db mice and in cultured endothelial cells. Journal Of Diabetes, [S.L.], v. 11, n. 8, p. 656-664, 28 fev. 2019.
